<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Isosorbide dinitrate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Isosorbide dinitrate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Isosorbide dinitrate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10775" href="/d/html/10775.html" rel="external">see "Isosorbide dinitrate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F184983"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Dilatrate-SR [DSC];</li>
<li>Isordil Titradose</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867275"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ISDN</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F185031"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antianginal Agent;</li>
<li>
                        Vasodilator</li></ul></div>
<div class="block doa drugH1Div" id="F184988"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Dilatrate SR has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2b95ab2-209a-45f7-bd41-cab078adb44c">Achalasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Achalasia (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sublingual [Canadian product]:</b> Immediate release: 5 mg administered 10 to 15 minutes before meals. <b>Note:</b> Clinical response is short acting and use does not provide complete relief of symptoms; consider risks before use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32773454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32773454'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc09e27a-efe5-434f-85df-59b0c70de3fd">Angina, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For prevention of recurrent angina, may use in combination with other anti-anginal therapy (eg, beta-blocker) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25249585','lexi-content-ref-23256914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25249585','lexi-content-ref-23256914'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: <b>Oral:</b> Initial: 5 to 20 mg 2 to 3 times daily; maintenance dose: 10 to 40 mg 2 to 3 times daily; allow for a 14-hour nitrate-free period after the evening dose and before the morning dose to minimize risk of tolerance.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: <b>Oral:</b> 40 to 160 mg/day; once daily dosing allows for an 18-hour nitrate-free period to minimize the risk of tolerance; maximum dose: 160 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sublingual [Canadian product]:</b> 5 to 10 mg every 2 to 4 hours; consider supplementing with 5 to 10 mg prior to activities that may provoke angina.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure </b>
<b>with reduced ejection fraction<b> (off-label use):</b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Alternative therapy for patients with persistent NYHA class III or IV heart failure with reduced ejection fraction (HFrEF) who cannot tolerate an angiotensin II receptor-neprilysin inhibitor, angiotensin-converting enzyme inhibitor, or angiotensin II receptor blocker or additional therapy in patients who have residual hypertension despite an optimal medical regimen for HFrEF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-Colucci.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-Colucci.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: Initial: 20 mg 3 times daily in combination with hydralazine; titrate dose as tolerated every ≥1 to 2 weeks; target dose: 40 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33446410','lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33446410','lexi-content-ref-35363499'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991776"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7333349','lexi-content-ref-2709744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7333349','lexi-content-ref-2709744'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3709643']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3709643'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not likely to be significantly dialyzed (large V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988933"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F184989"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Administer the lowest recommended adult daily dose initially and titrate upward. Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F184956"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, rebound hypertension, syncope, unstable angina pectoris</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache</p></div>
<div class="block coi drugH1Div" id="F184970"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to isosorbide dinitrate or any component of the formulation; concurrent use with phosphodiesterase inhibitors (sildenafil, tadalafil, vardenafil, or avanafil); concurrent use with riociguat.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Cardiogenic shock or risk of cardiogenic shock developing</p></div>
<div class="block war drugH1Div" id="F184953"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/bradycardia: Severe hypotension can occur; paradoxical bradycardia and increased angina pectoris can accompany hypotension. Orthostatic hypotension can also occur; ethanol can accentuate this. Use with caution in volume depletion and hypotension, and use with extreme caution with inferior wall MI and suspected right ventricular infarctions. Severe hypotension, particularly with upright posture, may occur with even small doses.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intracranial pressure increased: Nitrates may precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury (eg, intracranial hemorrhage, traumatic brain injury) (Rangel-Castilla 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Not recommended in patients with acute MI or HF (cannot easily reverse effects if adverse events develop).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertrophic cardiomyopathy: Avoid use in patients with hypertrophic cardiomyopathy with left ventricular outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (AHA/ACC [Ommen 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance: Appropriate dosing intervals are needed to minimize tolerance development. Tolerance can only be overcome by short periods of nitrate absence from the body. Dose escalation does not overcome this effect. When used for HF in combination with hydralazine, tolerance is less of a concern (Gogia 1995).</p></div>
<div class="block prod-avail drugH1Div" id="F57299289"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Dilatrate SR has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F184964"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dilatrate-SR: 40 mg [DSC] [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isordil Titradose: 5 mg [scored; contains fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isordil Titradose: 40 mg [scored; contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 20 mg, 30 mg, 40 mg</p></div>
<div class="block geq drugH1Div" id="F184949"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F184972"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Isordil Titradose Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $11.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $24.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Isosorbide Dinitrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.95 - $0.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.73 - $1.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.86 - $1.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $1.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $20.54 - $21.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867276"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 30 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Sublingual, Sublingual: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg [DSC]</p></div>
<div class="block adm drugH1Div" id="F184967"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Do not administer around the clock to prevent tolerance to nitrate effect; allow nitrate-free interval ≥14 hours (immediate-release products) and &gt;18 hours (sustained-release products). Do not chew or crush sublingual tablets or sustained-release formulations. <b>Note:</b> In patients with heart failure with reduced ejection fraction who are prescribed hydralazine in combination with isosorbide dinitrate, nitrate tolerance is prevented by coadministration of hydralazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7594088']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7594088'])">Ref</a></span>). When prescribed for this indication and in combination with hydralazine, isosorbide dinitrate can be administered 3 or 4 times daily with no nitrate-free period.</p>
<p style="text-indent:-2em;margin-left:2em;">IR products: For twice-daily dosing, consider administering at 8 AM and 1 PM. For 3-times-daily dosing, consider 8 AM, 1 PM, and 6 PM.</p>
<p style="text-indent:-2em;margin-left:2em;">ER products: Consider once daily in morning or twice-daily dosing at 8 AM and between 1 PM and 2 PM.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Capsule and tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Do not open capsule. Switch to IR tablet.</p></div>
<div class="block use drugH1Div" id="F184965"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina pectoris, prevention:</b> Prevention of angina pectoris due to coronary artery disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Due to slower onset of action, isosorbide dinitrate is not the drug of choice to abort an acute anginal episode.</p></div>
<div class="block off-label drugH1Div" id="F25474541"><span class="drugH1">Use: Off-Label: Adult</span><p>Achalasia; Heart failure with reduced ejection fraction</p></div>
<div class="block mst drugH1Div" id="F185039"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Isordil may be confused with Inderal, Isuprel, Plendil</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F185026"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F184958"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilmenidine: Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosiglitazone: Vasodilators (Organic Nitrates) may enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of ischemia and other adverse effects has been associated with this combination in some pooled analyses. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F12584821"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in some animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Nitric oxide donors, such as isosorbide, have been evaluated for cervical ripening and induction of labor (Abu-Zaid 2022; Ghosh 2016); however, use of isosorbide dinitrate is not currently recommended for this indication (ACOG 2009; NICE 2021). Nitric oxide donors have also been evaluated for the prevention of preterm birth (Duckitt 2014; Wilson 2022); additional study is needed for this indication and use is not currently recommended (McDougall 2023; WHO 2022).</p></div>
<div class="block brc drugH1Div" id="F20680678"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if isosorbide dinitrate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering isosorbide dinitrate to patients who are breastfeeding.</p></div>
<div class="block mop drugH1Div" id="F184962"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate </p></div>
<div class="block pha drugH1Div" id="F184952"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Isosorbide dinitrate and other nitrates form free radical nitric oxide. In smooth muscle, nitric oxide activates guanylate cyclase which increases guanosine 3’5’ monophosphate (cGMP) leading to dephosphorylation of myosin light chains and smooth muscle relaxation. Produces a vasodilator effect on the peripheral veins and arteries with more prominent effects on the veins. Primarily reduces cardiac oxygen demand by decreasing preload (left ventricular end-diastolic pressure); may modestly reduce afterload. Additionally, coronary artery dilation improves collateral flow to ischemic regions.</p></div>
<div class="block phk drugH1Div" id="F184969"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Sublingual tablet: ~2 to 5 minutes; Oral tablet and capsule (includes extended-release formulations): ~1 hour </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Sublingual tablet: 1 to 2 hours; Oral tablet and capsule (includes extended-release formulations): Up to 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 2 to 4 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively hepatic to conjugated active metabolites isosorbide 5-mononitrate and 2-mononitrate</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Highly variable (10% to 90%); increases with chronic therapy</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Parent drug: ~1 hour; Metabolites (5-mononitrate: 5 hours; 2-mononitrate: 2 hours)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F184973"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo isdn | Cedocard | Iso Mack | Isoket | Isordil | Sorbitrate | Vascardin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cortespasmo | Isoket | Isordil | Isosorbide vannier</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cedocard | Hexanitrat | Isoket | Isomack | Isostad | Sorbidilat | Vasorbate</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Isordil | Sorbidin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cedocard | Esordin | Isocard | Isordil | Lomilan | Sorbid | Vascardin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cedocard | Isordil | Sorbitrate</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Isonit</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Isodinit | Isoket | Kardiket</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Angil | Dinatrato de isossorbida | Isocord | Isogreen | Isorbid | Isordil | Isordil ap</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Acordin | Cedocard | Esconitro | Isoket | Isosifar | Sorbidilat</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Apo isdn</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Isorbid</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An qi lun | Ao shu jing | De yi xin | Iso Mack | Isoket | Li bo | Pu xin qing | Weixin haoxin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dinitrato de isosorbida | Dinitrato de isosorbide | Isocord | Isordil | Isosorbida</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo isdn | Cardiket | Cornilat | Dinisan | Isoket | Isomack | Isopelet | Maycor | Wesorbide</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Corovliss | Diconpin | Dignonitrat | Duranitrat | Ibd | Isdn | Isdn 3mm | Isdn al | Isdn beta | Isdn hexal | Isdn Isis | Isdn klast | Isdn merck | Isdn ratiopharm | Isdn Sandoz | Isdn stada | Iso Mack | Isodinit | Isoket | Jenacard | Maycor | Nitro-tablinen | Nitrosorbon</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Isocard | Isoket | Isordil | Nitorol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Iso Mack | Isoket | Isordil | Isosorbide</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cardiket | Isdn ratiopharm | Iso Mack | Isodinit | Isoket | Isolong | Isonit | Maycor | Nitrosorbid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cardiket | Cardioguard | Coronit | Dinitra | Iso Mack | Isomak | Isorbid | Isorbide | Isordil | Isosorbide</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Iso lacer</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Isosorbide</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dinit | Isonit | Nitrosid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dinitrate D Isosorbide Merck | Langoran lp | Risordan | Sorbitrate</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cedocard | Isoket | Isordil | Isosorb dinit | Isosorb dinit cox | Isosorb dinitrate | Isosorbid dinitrate | Isosorbid dinitrate kent pharm | Jeridin | Slomon xl | Soni Slo | Sorbid sa | Sorbitrate | Vascardin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Isotrate | Pensordil | Risordan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo isdn | Iso Mack | Isobid | Isoket | Isordil | Isorem | Nitorol</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Tinidil</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cardonit | Huma-sorbide | Isdn al | Isdn q | Iso Mack | Isoket | Isordil | Nitrosorbid | Nitrosorbon | Rigedal | Sorbonit</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cedocard | Farsorbid | Gasorbid | Hapisor | Isoket | Isomack | Isonat | Isorbid | Isordil | Isosorbide | Nosorbid | Sorbidin | Vascardin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cedocard | Isoket | Isordil</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cordil | Isocardide | Isolong | Isotard</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Anzidin | Cardicap | Cardicap tr | Iso Mack | Isonit | Isordil | Sorbicap | Sorbitrate</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Isordin awa | Vasordil</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Carvasin | Diniket | Nitrosorbide</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cardipine | Iso Mack | Isobide | Isocard | Isoket | Isordil | Isorem</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Carvanil | Circres | Conspit | Conspit taiyo | Cycobelan r | Diasera l | Frandol | Helpinin r | Hoxnol l | Isocoronal r | Isocoronal r amel | Isocoronal r nichiiko | Isosorbi Dinit | Isosorbide Dinitrate Tsuruhara | Kalliant | Kalliant merck hoei | Kalliant zensei | L ohnesgen mita | L-ohnesgen | Lubnol r amel | Lubnol r mg pharma | Nichirate | Nitorol | Nitrobide | Nitroslow | Nytosorbide | Rifatac | Sawadol | Sornilart | Sornitron | Storo | Sulendmin | Sulendmin choseido</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Anginal</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Angibid | Angibid sr | Carso | Carsodil | Iso Mack | Isobin | Isodil | Isoket | Isoket retard | Isomide | Isosorbide | Solbid</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Isoket | Isomack | Isordil</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo isdn | Apo isosorbide | Iso Mack | Isoket | Isordil | Novo Sorbide | Risordan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo isdn | Cardiket | Cardonit | I s d n | Isdn | Isodinit | Isoket | Isolong | Isomack | Isosorb | Isosorbide dinitra | Maycor | Nitrosorbid | Nitrosorbide</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cedocard | Isdn | Isodinit | Isoket | Isomack | Isordil | Sorbitrate</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cardiket | Cardonit | Dinitreks | Isdn | Isodinit | Isoket | Isomack | Isosorb | Isosorbide | Maycor | Nitrosorbid | Nitrosorbide | Sorbidin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Apo isdn | Disorlon | Langoran | Risordan | Risordan l.p.</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Biderit | Biordyn | Debisor | Dinorbide | Insucar | Isoket | Isorbid | Isorbid ap | Isosorbida | Isosorbida arlex | Isosorbida carbel | Isosorbida kendall</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Angsobide | Apo isdn | Iso Mack | Isobid | Isoket | Isordil | Nitorol | Solbid | Sorbidin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cedocard | Isordil | Isosorbide Dinitraat CF | Isosorbide Dinitraat Katwijk | Isosorbidedinitraat | Isosorbidedinitraat A | Isosorbidedinitraat Actavis | Isosorbidedinitraat alpharma | Isosorbidedinitraat CF | Isosorbidedinitraat flx | Isosorbidedinitraat Merck | Isosorbidedinitraat pch | Isosorbidedinitraat Ratiopharm | Isosorbidedinitraat Sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Sorbangil</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Coronex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cardosor | Dilangin | Dinitrato de isosorbida | Isoket | Isorbide | Isosorbida dinitrato | Isotrate</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bideren | Isobar | Isobenil | Isoket | Isordil | Nitorol | Nitrosorbon | Novisor | Socorro | Sorbance 5 | Sornitrat | Trindil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Isdin | Isobid | Isocord-d10 | Isocord-d5 | Isoday | Isoket | Isonit | Isoprime | Isordil | Isornit | Mayadil | Sorbid | Tinidil</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo isdn | Cardiosorbid | Cardonit | Cornilat | Iso puren | Isodinit | Isoket | Isomack | Maycor | Risordan | Sorbonit</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dilatrate | Isoditrate | Isordil | Sorbitrate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dinitrato de isossorbida | Flindix | Isoket | Isopront</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cardil | Isomack retard | Isordil | Terdil</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Wesorbide</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dinicord retard | Diniter sr | Isolong | Isosorbid dinitrat arena | Izosorbid dinitrat | Maycor</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cardiket | Cardix | Dinisorb | Dinorb | Isacardin | Isodinit | Isoket | Isomack | Isosorb | Isosorbid | Isosorbide dinitrat | Kardonit | Nitrosorbid | Sorbidin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo isosorbide dinitrate | Iso Mack | Isobide | Isoket | Isordil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Sorbangil</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Angsobide | Apo isdn | Isoket | Isomack | Isordil</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Iso Mack | Tinidil</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cardiket | Dinisan | Isoket | Isomack | Isopelet | Maycor</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Angitrit | Apo isdn | Cedocard | Corodil | Hartsorb | Iso | Iso Mack | Isobide | Isobinate | Isoket | Isorbide | Isordil | Isorem | Isosorb | Isosorbide | Isotrate | Izo | Nitorol | Soni Slo | Sorbidin | Sorbitrate | Sornil | Tinidil</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Apo isdin | Isodil | Langoran | Pensordil | Risordan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cardioket | Isonit | Isordil ayerst | Nitrofix | Sorbid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Angidil | Cedocard | Iso Mack | Isobide | Isocin | Isoket | Isordil | Isosorbide | Nitorol | Sorbangil | Sorbitrate | Sorcilin | U-Sorbide</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cardiket | Cardiket retard | Dicor long | Iso Mack | Iso mick | Iso mik | Isodinitrat | Isoket | Isosorb | Izosorbit | Nitrosorbid | Nitrosorbit</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cardionit | Conducil | Isoket | Nitransur</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dinitrato de isosorbida | Dinitrato de isosorbide | Isoket | Isomack | Isordil</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Biresort | Nadecin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cedocard | Isoket | Isordil | Rolab-isosorbide dinitrate</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Apo isdn</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-35803111">
<a name="35803111"></a>Abu-Zaid A, Alshahrani MS, Al-Matary A, et al. Isosorbide mononitrate for cervical ripening during labour induction: a systematic review and meta-analysis of 23 randomized controlled trials. <i>Eur J Obstet Gynecol Reprod Biol.</i> 2022;276:38-46. doi:10.1016/j.ejogrb.2022.06.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/35803111/pubmed" id="35803111" target="_blank">35803111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19623003">
<a name="19623003"></a>American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 107: induction of labor. <i>Obstet Gynecol</i>. 2009;114(2 Pt 1):386-397. doi:10.1097/AOG.0b013e3181b48ef5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/19623003/pubmed" id="19623003" target="_blank">19623003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25249585">
<a name="25249585"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA task force members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. <i>Circulation</i>. 2014;130(25):e344-e426. doi:10.1161/CIR.0000000000000134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/25249585/pubmed" id="25249585" target="_blank">25249585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21444888">
<a name="21444888"></a>Anderson JL, Adams CD, Antman EM, et al, "2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines," <i>Circulation</i>, 2011, 123(18):e426-579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/21444888/pubmed" id="21444888" target="_blank">21444888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289388">
<a name="15289388"></a>Antman EM, Anbe SC, Alpert JS, et al, “ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),” <i>Circulation</i>, 2004, 110(5):588-636. Available at http://www.circulationaha.org/cgi/content/full/110/5/588<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/15289388/pubmed" id="15289388" target="_blank">15289388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3709643">
<a name="3709643"></a>Bauer H, Laufen H, Franz HE. Isosorbide dinitrate in plasma and dialysate during haemodialysis. <i>Eur J Clin Pharmacol</i>. 1986;30(2):187-190. doi:10.1007/BF00614300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/3709643/pubmed" id="3709643" target="_blank">3709643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7333349">
<a name="7333349"></a>Bogaert MG, Rosseel MT, Boelaert J, Daneels R. Fate of isosorbide dinitrate and mononitrates in patients with renal failure. <i>Eur J Clin Pharmacol</i>. 1981;21(1):73-76. doi:10.1007/BF00609591<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/7333349/pubmed" id="7333349" target="_blank">7333349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9935041">
<a name="9935041"></a>Cheitlin MD, Hutter AM Jr, Brindis RG, et al, “ACC/AHA Expert Consensus Document. Use of Sildenafil (Viagra) in Patients With Cardiovascular Disease. American College of Cardiology/American Heart Association,” <i>J Am Coll Cardiol</i>, 1999, 33(1):273-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/9935041/pubmed" id="9935041" target="_blank">9935041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3520315">
<a name="3520315"></a>Cohn JN, Archibald DG, Ziesche S, et al, "Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study," <i>N Engl J Med</i>, 1986, 314(24):1547-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/3520315/pubmed" id="3520315" target="_blank">3520315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2057035">
<a name="2057035"></a>Cohn JN, Johnson G, Ziesche S, et al, "A Comparison of Enalapril With Hydralazine-Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure," <i>N Engl J Med</i>, 1991, 325(5):303-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/2057035/pubmed" id="2057035" target="_blank">2057035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colucci.2019">
<a name="Colucci.2019"></a>Colucci WS. Secondary pharmacologic therapy in heart failure with reduced ejection fraction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DilatrateSR.1">
<a name="DilatrateSR.1"></a>Dilatrate-SR (isosorbide dinitrate sustained-release capsules) [prescribing information]. Chesterbrook, PA: Auxilium Pharmaceuticals; October 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24809331">
<a name="24809331"></a>Duckitt K, Thornton S, O'Donovan OP, Dowswell T. Nitric oxide donors for treating preterm labour. <i>Cochrane Database Syst Rev</i>. 2014;2014(5):CD002860. doi:10.1002/14651858.CD002860.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/24809331/pubmed" id="24809331" target="_blank">24809331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2709744">
<a name="2709744"></a>Evers J, Bonn R, Boertz A, Cawello W, Dickmans HA, Weiss M. Pharmacokinetics of isosorbide dinitrate, isosorbide-2-nitrate and isosorbide-5-nitrate in renal insufficiency after repeated oral dosage. <i>Klin Wochenschr</i>. 1989;67(6):342-348. doi:10.1007/BF01741389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/2709744/pubmed" id="2709744" target="_blank">2709744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al, “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” <i>Circulation</i>, 2012, 126(25):3097-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918616">
<a name="27918616"></a>Ghosh A, Lattey KR, Kelly AJ. Nitric oxide donors for cervical ripening and induction of labour. <i>Cochrane Database Syst Rev</i>. 2016;12(12):CD006901. doi:10.1002/14651858.CD006901.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/27918616/pubmed" id="27918616" target="_blank">27918616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7594088">
<a name="7594088"></a>Gogia H, Mehra A, Parikh S, et al, “Prevention of Tolerance to Hemodynamic Effects of Nitrates With Concomitant Use of Hydralazine in Patients With Chronic Heart Failure,” <i>J Am Coll Cardiol</i>, 1995, 26(7):1575-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/7594088/pubmed" id="7594088" target="_blank">7594088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISDN.1">
<a name="ISDN.1"></a>ISDN (isosorbide dinitrate) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; June 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IsoDitrate.1">
<a name="IsoDitrate.1"></a>IsoDitrate (isosorbide dinitrate) extended-release tablets [prescribing information]. Middlesex, NJ: Corepharma: April 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IsordilTitradose.1">
<a name="IsordilTitradose.1"></a>Isordil Titradose (isosorbide dinitrate) tablets [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NorthstarRx.1">
<a name="NorthstarRx.1"></a>Isosorbide Dinitrate (tablets, USP [oral]) [prescribing information]. Memphis, TN: Northstar Rx LLC; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33446410">
<a name="33446410"></a>Maddox TM, Januzzi JL Jr, Allen LA, et al; Writing Committee. 2021 update to the 2017 ACC Expert Consensus Decision Pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee.<i> J Am Coll Cardiol</i>. 2021;77(6):772-810. doi:10.1016/j.jacc.2020.11.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/33446410/pubmed" id="33446410" target="_blank">33446410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37464260">
<a name="37464260"></a>McDougall ARA, Hastie R, Goldstein M, et al. New medicines for spontaneous preterm birth prevention and preterm labour management: landscape analysis of the medicine development pipeline. <i>BMC Pregnancy Childbirth</i>. 2023;23(1):525. doi:10.1186/s12884-023-05842-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/37464260/pubmed" id="37464260" target="_blank">37464260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35438865">
<a name="35438865"></a>National Institute for Health and Care Excellence. Inducing labour. London: National Institute for Health and Care Excellence (NICE); 2021. https://www.nice.org.uk/guidance/ng207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/35438865/pubmed" id="35438865" target="_blank">35438865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23256914">
<a name="23256914"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. <i>J Am Coll Cardiol</i>. 2013;61(4):e78-e140. doi:10.1016/j.jacc.2012.11.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/23256914/pubmed" id="23256914" target="_blank">23256914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3574424">
<a name="3574424"></a>Parker JO, Fanell B, Lahey KA, et al, “Effect of Intervals Between Doses on the Development to Tolerance to Isosorbide Dinitrate,” <i>N Engl J Med</i>, 1987, 316(23):1440-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/3574424/pubmed" id="3574424" target="_blank">3574424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18514825">
<a name="18514825"></a>Rangel-Castilla L, Gopinath S, Robertson CS. Management of intracranial hypertension. [published correction appears in <i>Neurol Clin</i>. 2008;26(3):xvii]. <i>Neurol Clin</i>. 2008;26(2):521-41, x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/18514825/pubmed" id="18514825" target="_blank">18514825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15533851">
<a name="15533851"></a>Taylor AL, Ziesche S, Yancy C, et al, "Combination of Isosorbide Dinitrate and Hydralazine in Blacks With Heart Failure," <i>N Engl J Med</i>, 2004, 351(20):2049-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/15533851/pubmed" id="15533851" target="_blank">15533851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18041888">
<a name="18041888"></a>Trujillo TC and Dobesh PP, “Traditional Management of Chronic Stable Angina,” <i>Pharmacotherapy</i>, 2007, 27(12):1677-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/18041888/pubmed" id="18041888" target="_blank">18041888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32773454">
<a name="32773454"></a>Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. <i>Am J Gastroenterol</i>. 2020;115(9):1393-1411. doi:10.14309/ajg.0000000000000731<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/32773454/pubmed" id="32773454" target="_blank">32773454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35947046">
<a name="35947046"></a>Wilson A, Hodgetts-Morton VA, Marson EJ, et al. Tocolytics for delaying preterm birth: a network meta-analysis (0924). <i>Cochrane Database Syst Rev.</i> 2022;8(8):CD014978. doi:10.1002/14651858.CD014978.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-dinitrate-drug-information/abstract-text/35947046/pubmed" id="35947046" target="_blank">35947046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). WHO recommendation on tocolytic therapy for improving preterm birth outcomes [Internet]. Geneva: World Health Organization; 2022. <a href="https://www.ncbi.nlm.nih.gov/books/NBK585023/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK585023/</a>. Accessed November 8, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8580 Version 411.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
